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 Abstract 
 Background. Sub-Saharan Africa experiences an epidemic surge in hypertension. Studies in African Americans led to the 
recommendation to initiate antihypertensive treatment in Blacks with a diuretic or a low-dose fi xed combination including 
a diuretic. We mounted the Newer versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial 
to compare in native African patients a fi xed combination of newer drugs, not involving a diuretic, with a combination of 
older drugs including a diuretic.  Methods. Patients aged 30 – 69 years with uncomplicated hypertension (140 – 179/90 – 109 
mmHg) and two or fewer associated risk factors are eligible. After a 4-week run-in period off treatment, 180 patients will 
be randomized to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg or amlodipine/valsartan 5/160 mg. To attain and 
maintain blood pressure below 140/90 mmHg during 6 months of follow-up, the doses of bisoprolol and amlodipine in 
the combination tablets will be increased to 10 mg/day with the possible addition of  α -methyldopa or hydralazine. NOAAH 
is powered to demonstrate a 5-mmHg between-group difference in sitting systolic pressure with a two-sided  p -value of 
0.01 and 90% power. NOAAH is investigator-led and complies with the Helsinki declaration.  Results. Six centers in four 
sub-Saharan countries started patient recruitment on September 1, 2010. On December 1, 195 patients were screened, 
171 were enrolled, and 51 were randomized and followed up. The trial will be completed in the third quarter of 2011. 
 Conclusions. NOAAH (NCT01030458) is the fi rst randomized multicenter trial of antihypertensive medications in hyper-
tensive patients born and living in sub-Saharan Africa. 
 Key Words:  Antihypertensive therapy ,  health policy and outcome research ,  randomized clinical trial ,  special populations 
 Introduction 
 Poverty, famine and infectious diseases, such as malaria 
and AIDS, are well-known and long-standing causes 
of premature death and disability in sub-Saharan 
Africa (1). However, this region of the world also faces 
an emerging epidemic of cardiovascular disease (2 – 4). 
Global trade and urbanization (5) expose developing 
populations to an unhealthy lifestyle, which leads to 
hypertension, obesity, diabetes mellitus and dyslipi-
demia (2,3,5). Whereas hypertension virtually did 
Blood Pressure, 2011; 20: 256–266
ISSN 0803-7051 print/ISSN 1651-1999 online © 2011 Scandinavian Foundation for Cardiovascular Research
DOI: 10.3109/08037051.2011.572614
B
lo
od
 P
re
ss
 D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
K
U
 L
eu
ve
n 
 T
ijd
sc
hr
ift
en
 o
n 
10
/0
6/
11
Fo
r p
er
so
na
l u
se
 o
nl
y.
  Rationale and design of NOAAH  257
not exist in Black Africa in the fi rst half of the 20th 
century (6), currently, by 65 years of age and over, 
hypertension affects 30% up to 60% of African 
Blacks (7). This proportion is approaching the 
60 – 70% range for African Americans of similar age 
(7). Lowering blood pressure and controlling hyper-
tension is key in cardiovascular prevention. 
 Regarding the choice of the initial antihyperten-
sive agent, the 2003 guidelines of the World Health 
Organization and the International Society of Hyper-
tension (WHO/ISH) (8) state that for the majority 
of patients without a compelling indication for 
another class of drug, a low-dose diuretic should be 
considered as the fi rst choice of therapy on the basis 
of comparative trial data, availability and cost. 
The guidelines published by the European Societies 
of Hypertension and Cardiology (ESH/ESC) (9) 
and the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC7) (10) consider the initiation of anti-
hypertensive treatment with combination therapy as 
an alternative to titrating, rotating and sequentially 
combining blood pressure lowering drugs of different 
classes. Using the combination of two drugs at a low 
dose avoids side-effects (9,10) and increases adher-
ence (11). Moreover, most patients require a combina-
tion of two or more drugs to achieve blood pressure 
control (9,10). Combination therapy gets round the 
laborious and time-consuming search for an effective 
monotherapy, so that blood pressure targets can be 
reached faster (9). 
 Rationale and design of the trial 
 Several randomized clinical trials published since the 
WHO/ISH guidelines were issued, proved that a 
combination of newer antihypertensive agents, com-
pared with older antihypertensive agents (12) or 
combinations including a diuretic (13) lowered blood 
pressure more with fewer metabolic side-effects and, 
more importantly, further reduced the incidence 
of cardiovascular complications. In line with these 
observations (12,13) and guidelines issued by Euro-
pean (9) American (10,14) African (15 – 17) and 
international (8,18) expert committees, drug compa-
nies are now increasingly marketing fi xed combina-
tions of antihypertensive drugs. However, while 
sub-Saharan Africa is passing through an epidemic 
surge in hypertension and associated cardiovascular 
complications, to our knowledge, few previous trials 
assessed the effi cacy of a combination of newer 
versus older antihypertensive drugs in Black hyper-
tensive patients born and living in Africa. As a rule, 
fi ndings in Black patients living in the USA or Europe 
are extrapolated to African Blacks. Such extrapolation 
does not account for differences in natural selection 
in previous generations (19) ethnic admixture (20), 
living environments and life style (21). We therefore 
mounted the Newer Versus Older Antihypertensive 
Agents in African Hypertensive Patients (NOAAH) 
trial ( NCT01030458) to compare in Black hyperten-
sive patients born and living in sub-Saharan Africa 
the blood pressure lowering effi cacy of a combina-
tion of newer versus older antihypertensive agents. 
Patients will be randomized to 6 months of treatment 
with either the combination of an angiotensin II type-1 
receptor blocker and a dihydropyridine calcium-
channel blocker or the combination of a betablocker 
with a thiazide diuretic. 
 Primary and secondary outcomes 
 The primary outcome is the level of systolic blood 
pressure achieved on randomized treatment and 
measured with the patient in the seated position. 
Secondary outcomes are the time interval required 
after randomization to achieve blood pressure con-
trol defi ned as a level below 140 mmHg systolic and 
90 mmHg diastolic, the incidence of adverse events 
(including metabolic side-effects), and the adherence 
to the study medication and dropout rate. 
 Sample size 
 As in previous studies the standard deviation of the 
changes in systolic blood pressure is around 12 mmHg, 
180 randomized patients, 90 per treatment group, are 
required to demonstrate a 5-mmHg between-group 
difference in the achieved systolic blood pressure 
with a two-sided  p -value of 0.01 and 90% power. 
 General design 
 Eligible patients are treatment na ï ve or previously 
treated patients of either sex with grade-1 or grade-2 
hypertension (9). The study starts with a screening 
visit, at which informed consent is obtained, followed 
by a run-in period with two subsequent visits at 
2-week intervals (Figure 1). To document the external 
validity of the NOAAH results, investigators will 
keep a log of the patients screened for enrollment. 
Patients entering the run-in period provide informed 
consent. Literate patients sign and date the informed 
consent form. Illiterate patients provide a fi ngerprint 
in the presence of an independent witness. During 
the run-in period, antihypertensive drug treatment is 
discontinued and lifestyle changes are recommended. 
After randomization, patients are followed up for 
6 months with visits on randomized treatment sched-
uled after 2 and 4 weeks, and monthly thereafter 
until the end of the study. 
 Selection of patients 
 Eligible patients are 30 – 69 years old. Hypertension 
must be uncomplicated with a maximum of two 
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additional risk factors, as defi ned in the 2007 ESC/
ESH guideline (9). The blood pressure determining 
eligibility is the average of three consecutive readings 
obtained with patients in the seated position 4 weeks 
after enrollment and after stopping antihypertensive 
drug treatment in previously treated patients. Stand-
ing systolic blood pressure, the average of three 
consecutive readings immediately after patients 
assumed the upright position, must be at least 
110 mmHg. Women with childbearing potential must 
apply effective contraception. 
 The presence of three or more risk factors, a history 
of cardiovascular disease and diabetes mellitus (22) are 
exclusion criteria. Previously treated patients should 
not have a compelling indication, according to the 
ESC/ESH guideline (9), to continue antihyperten-
sive drug treatment and should not take more than 
a single drug at the screening visit. Low-dose com-
bination tablets are counted as a single drug. Atrial 
fi brillation is an exclusion criterion as well as elec-
trocardiographic left ventricular hypertrophy with 
strain pattern or electrocardiographic left ventricular 
hypertrophy defi ned as a Sokolow – Lyon index larger 
than 38 mm (3.8 mV) or a Cornell voltage   dura-
tion QRS index larger than 2440 mm   ms (23 – 25). 
Patients with renal disorders are excluded. Renal 
dysfunction is a serum creatinine concentration, 
which is higher than 1.4 mg/dl in women or higher 
than 1.5 mg/dl in men (26). Proteinuria and hema-
turia as detected by a semi-quantitative dipstick test 
are also exclusion criteria. Severe non-cardiovascular 
disorders, psychiatric illness and substance abuse 
lead to exclusion. 
 Treatment 
 Treatment policies in NOAAH are in line with 
current guidelines (8 – 10,14 – 16,18). Blood pressure 
must be reduced to   140 mmHg systolic and 
  90 mmHg diastolic. The goal blood pressure should 
be attained by up-titration of the randomized medi-
cation and if necessary by the combination of other 
antihypertensive drugs with the fi rst-line drugs, 
avoiding crossover between the two arms of the 
study. 
 Lifestyle 
 The lifestyle measures to be recommended and 
reinforced during the run-in period and randomized 
follow-up include cessation of smoking, moderation 
of excessive alcohol intake, regular physical activity, 
weight reduction in overweight or obese patients, 
dietary measures to control dyslipidemia, and a 
moderation of salt intake. 
 Treatment before randomization 
 During the run-in period, patients should not take 
any blood pressure lowering drugs. Patients can con-
tinue medical treatment for non-cardiovascular dis-
eases. The use of aspirin and lipid lowering drugs, if 
indicated, is encouraged, but at the discretion of the 
clinical investigator. 
 Procedures at randomization 
 Before the start of the trial, the Studies Coordinating 
Center (SCC) generated a list of treatment allocation 
with balanced randomization per center, using per-
muted blocks of four consecutive patients within 
each center. Before randomization, staff at SCC 
check all entry criteria as reported by the investiga-
tors in the case report forms (CRFs) for the screen-
ing visit (V S ) and the two run-in visits (R 1 and R 2 ). 
 Treatment after randomization 
 The study medication consists of the combination of 
6.25 mg hydrochlorothiazide plus 5 mg bisoprolol to 
be up-titrated to 6.25 mg hydrochlorothiazide plus 
10 mg bisoprolol (Lodoz ® ) in the reference group and 
of the combination of amlodipine 5 mg plus valsartan 
160 mg to be up-titrated to amlodipine 10 mg with 
valsartan 160 mg (Exforge ® ) in the experimental 
 
Figure 1. Schematic representation of the trial. HCTZ indicates hydrochlorothiazide. 
B
lo
od
 P
re
ss
 D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
K
U
 L
eu
ve
n 
 T
ijd
sc
hr
ift
en
 o
n 
10
/0
6/
11
Fo
r p
er
so
na
l u
se
 o
nl
y.
  Rationale and design of NOAAH  259
group. Patients should take the study medication in 
the morning. If patients experience side-effects, the 
randomized study medication can be continued at 
the lower dose or discontinued and replaced by other 
antihypertensive drugs. To achieve blood pressure 
control, the fi rst-line study medication has to be up-
titrated and combined with other antihypertensive 
drugs. In the two treatment groups,  α -methyldopa 
(Aldomet ® ) up to 2 g per day will be used, if the 
blood pressure remains uncontrolled on the maxi-
mally tolerated dose of the randomized medication. 
Hydralazine up to 200 mg per day is an alternative to 
Aldomet ® . Adding antihypertensive drugs should never 
lead to crossing the lines of randomization. In the refer-
ence group, calcium-channel blockers and blockers 
of the renin system (angiotensin-converting enzyme 
inhibitors or angiotensin II type-1 receptor blockers) 
cannot be used. Conversely, in the group on new drugs, 
beta blockers and diuretics should not be prescribed. 
 Drug accountability 
 SCC shipped Lodoz ® , Exforge ® and Aldomet ® to 
the recruiting clinical sites. To track the fl ow of med-
ication, each box of drugs carries a unique identi-
fi cation number. Patients should return unused 
medication at the next visit. Investigators count the 
number of unused pills. They store used (empty) or 
partially used boxes of study medication for audits. 
Patients are classifi ed as compliant, if they took at 
least 80% of the prescribed study medication and if 
they did not miss any dose on the days of the clinic 
visits. Whenever drugs are dispensed or recuperated 
investigators complete a drug accountability form to 
be forwarded to SCC along with the visit CRF. 
 Premature discontinuation of treatment 
 Doctors can prematurely withdraw patients from the 
trial. Valid reasons include any condition that accord-
ing to the doctor ’ s clinical judgment puts a patient 
at risk if the study medication is continued, the 
necessity to administer antihypertensive drugs that 
lead to crossover, uncontrolled hypertension on the 
maximally tolerated study medication or orthostatic 
hypotension. Uncontrolled hypertension is a blood 
pressure of at least 180 mmHg systolic or 110 mmHg 
diastolic, confi rmed within 1 week after the initial 
measurement. Orthostatic hypotension is a drop in 
the systolic blood pressure upon standing by at least 
40 mmHg. At any time, patients can withdraw con-
sent or leave the trial, for instance because of symp-
toms or diffi culties to reach the clinical sites. 
 Measurements 
 Accurate and reproducible measurements are essen-
tial for answering the research questions of NOAAH. 
Table I lists the measurements to be obtained at 
each visit. 
 Blood pressure 
 Blood pressure will be measured by means of vali-
dated (27) oscillometric OMRON 705IT recorders 
(OMRON Healthcare Europe BV, Nieuwegein, The 
Netherlands) according to the ESC/ESH guideline 
(28). If, at the screening visit, the blood pressure 
differences between both arms are less than 10 mmHg 
systolic and diastolic, all blood pressure readings 
throughout the trial are obtained at the non-dominant 
arm. Otherwise, the arm giving the highest blood 
pressure readings must be chosen. A standard cuff 
with an infl atable bladder of 22   12 cm will be used 
if arm circumference is less than 32 cm and cuffs 
with a 35   15 cm bladder on larger arms. If pos-
sible, during the whole trial, each patient ’ s blood 
pressure should be measured at the same arm, using 
the same device and the same cuff size. A unique 
number identifi es each OMRON recorder. For each 
device, investigators keep a log documenting 
3 monthly checks of calibration against a mercury 
sphygmomanometer, defects, and other maintenance 
procedures, such as for instance the use of a new cuff 
or bladder. 
 Electrocardiogram 
 Investigators record standard 12-lead ECGs by 
means of the paperless Cardiax device (http://www.
rdsm.eu/cardiax.html), interfaced with a computer. 
Using the Cardiax software, version 3.50.2 (RDSM, 
Hasselt, Belgium), the ECG recordings are locally 
printed both electronically and as a hard copy, using 
a PDF printer. Via the web, the ECG data are elec-
tronically delivered to SCC as an email attachment. 
Voltages and duration of ECG waves are derived 
from 16-s ECGs, while 5-min recordings are ana-
lyzed for the spectral variability of heart rate in the 
frequency domain. 
 Other measurements 
 A standardized questionnaire validated in previous 
trials (29,30) will be administered to assess side-
effects. Biochemical measurements include hemo-
globin, hematocrit, red and white blood cell counts, 
serum potassium, creatinine and total cholesterol, 
blood glucose, and a dipstick test on fresh urine to 
detect glucosuria, proteinuria and hematuria. Ali-
quots of serum (2 – 5 ml) and urine (5 ml) are stored 
at  – 20 ° C or less to address unforeseen issues. Four 
centers perform pulse wave analysis and measure the 
central blood pressure and carotid – femoral pulse 
wave velocity by means of the SphygmoCor device 
and software version 7.1 (AtCor Medical Pty. Ltd., 
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West Ryde, New South Wales, Australia), as previously 
described (31). 
 Management 
 NOAAH is an investigator-initiated and investigator-
led randomized clinical trial, partially supported by 
Novartis. NOAAH involves seven clinical sites, all 
located in sub-Saharan Africa, the Hypertension 
Unit at the University of Kinshasa as sponsor and 
the Division of Hypertension and Cardiovascular 
Rehabilitation at the University of Leuven as coordi-
nating center. 
 Ethics 
 NOAAH fully complies with the guidelines for good 
clinical practice outlined in the Helsinki declaration 
(32), as well as with all international, European and 
national regulations. Each participating center received 
approval from the local Institutional Review Board 
and, if applicable, from National Regulatory Authori-
ties. The sponsor obtained ethical approval from the 
Ethics Committee of the Faculty of Medicine, Uni-
versity of Kinshasa, Democratic Republic of Congo. 
 Role of the sponsor 
 The Hypertension Unit at the University of Kinshasa 
will be responsible for the organization and execution 
of site visits to the clinical centers. 
 Role of the coordinating offi ce 
 SCC in Leuven is responsible for the overall coordi-
nation of the trial and for quality control and assur-
ance. SCC will construct and maintain the NOAAH 
database, run the statistical analysis, and in collabo-
ration with the clinical sites and the sponsor publish 
the NOAAH reports. During the trial, investigators 
will remain blinded to the results of the trial. This 
does not preclude publication of progress reports on 
recruitment and baseline characteristics. 
 Flow of data 
 SCC developed the CRFs as interactive PDF forms, 
which investigators complete at the clinical sites and 
print for the local patient fi les. XML fi les exported 
from the PDFs are sent to SCC as email attach-
ments. After quality control and addition of the codes 
for symptoms, diseases and concurrent medications 
at SCC, the XML fi les are directly imported into the 
SAS database, using the SAS XML Mapper, version 
9.2. Conversely, PDFs generated from the received 
XML fi les at SCC can be returned to the clinical 
sites, if questions arise or issues need conformation. 
This setup makes immediate exchange of informa-
tion possible and avoids data entry at SCC. Each 
clinical site maintains a local database of PDF and 
XML fi les ordered by visit and type of information. 
The fl ow of information as organized in NOAAH 
does not require continuous access to Internet and 
allows for power cuts, which might occur in some 
sub-Saharan countries. It also avoids double data 
entry at SCC and enables short turnaround times in 
the exchange of information between the clinical 
sites and SCC, which proved to be essential to guar-
antee quality and to standardize the collection of 
information. 
 Statistical analysis 
 For database management and statistical analysis 
SAS software, version 9.2 (SAS Institute Inc., Cary, 
NC, USA) is used. The software was validated 
according to the 21 Code of Federal Regulations 
(http://www.fda.gov/cder/offi ces/ods/ regs.htm). The 
primary and secondary hypotheses related to blood 
pressure will be assessed in two cohorts of patients. 
The intention-to-treat analysis includes all patients 
who have at least one evaluation available after ran-
domization. In case of missing data, the last observa-
tion will be carried forward. The per-protocol 
analysis involves all patients, who fulfi lled the eligibil-
ity criteria, took at least 80% of the prescribed study 
medication, did not take any drugs prohibited by the 
protocol, and underwent a complete evaluation at the 
end of follow-up. Adverse events and dropouts will 
be assessed in all randomized patients, who took at 
least one dose of the study medication. All statistical 
tests will be two-sided. 
 The primary and secondary endpoints measured 
on a continuous scale will be analyzed by repeated-
measures analysis of variance. The secondary analy-
sis will also include binary blood pressure endpoints, 
which will be analyzed by means of McNemar ’ s test. 
Responders have a decrease in their sitting systolic 
 Table I. Measurements by visit. 
Months  – 1  – ½ 0   ½   1   2   3   4   5   6
Visits S R 1 R 2 V  ½  V 1 V 2 V 3 V 4 V 5 V T 
Blood pressure x x x x x x x x x x
Tablet count x x x x x x x x
Blood sample x x x
Fresh urine 
sample
x x x
Questionnaire x x x x
Fundoscopy x x
ECG x x x x
PWA and PWV x x x x
 ECG indicates electrocardiogram. PWA and PWV indicate and 
measurement of pulse wave velocity by means of the SphygmoCor 
device and software at four centers. 
B
lo
od
 P
re
ss
 D
ow
nl
oa
de
d 
fr
om
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
K
U
 L
eu
ve
n 
 T
ijd
sc
hr
ift
en
 o
n 
10
/0
6/
11
Fo
r p
er
so
na
l u
se
 o
nl
y.
  Rationale and design of NOAAH  261
blood pressure on randomized treatment by at least 
10%. Controlled patients maintain a blood pressure 
level below 140 mmHg systolic and 90 mmHg dia-
stolic. Time to blood pressure control will be evalu-
ated using Kaplan – Meier estimates, the log-rank test 
and Cox regression. To determine the profi le of con-
trolled patients or responders, the continuous and 
binary blood pressure endpoints will be subjected to 
multiple (stepwise) linear and logistic regressions. 
 While accounting for concurrent medications, 
the safety and tolerability analysis will involve clinical 
signs and symptoms, adverse events, laboratory tests 
on blood and urine, and the ECG measurements. 
Adverse events will be coded using the ICD code, 
version 10 (http://www.who.int/classifi cations/apps/
icd/icd10online) and concomitant medications accord-
ing to the coding system applied in the Flemish 
Study on Genes, Environment and Health Outcomes 
(33,34) and in the European Project on Genes in 
Hypertension (35). After conversion to SI units, the 
biochemical measurements will be normalized to a 
unique reference range (36). To facilitate identifi ca-
tion of outliers, normalized values at baseline and 
follow-up will be plotted against each other. 
 Time line 
 The fi rst NOAAH investigators ’ meeting took place 
in Paris, France, on December 18, 2008 with a sec-
ond meeting in Abuja, Nigeria, on September 26, 
2009. A training workshop was organized in Doula, 
Cameroon, on August 26 – 27, 2010. It took almost 
2 years to obtain the required approvals, to mount 
the required infrastructure and to train the clinical 
investigators. Patient recruitment started on Septem-
ber 1, 2010. On December 1, 195 patients had been 
screened, 171 had been enrolled and 51 were ran-
domized and followed up (Figure 2). The study 
should be completed by the third quarter of 2011 and 
submitted for publication by the end of that year. 
 Discussion 
 To our knowledge, NOAAH is the fi rst randomized 
multicenter clinical trial on antihypertensive thera-
pies that is exclusively running in sub-Saharan Africa. 
The underlying hypothesis is that in Blacks born and 
living in Africa the combination of newer agents will 
be more effective in blood pressure lowering and in 
achieving blood pressure control with fewer side-
effects than the combination of older drugs. If these 
assumptions hold true, they challenge the current 
recommendation of the WHO/ISH (8) to start 
 antihypertensive treatment with diuretics in Black 
hypertensive patients, in particular because lowering 
systolic blood pressure (37 – 40) and early blood pres-
sure control (12,41) are essential for the prevention 
of cardiovascular complications. Although according 
to our hypothesis newer drugs will be more effective 
than older agents, all statistical tests will be two-
sided. Because blood pressure measurement is auto-
mated in NOAAH, the primary endpoint is measured 
free of observer bias. 
 NOAAH will generate information that is helpful 
in addressing the epidemic of cardiovascular disease 
in sub-Saharan Africa (42). Reliable statistics on the 
prevalence or incidence of cardiovascular morbidity 
and mortality in sub-Saharan Africa are scarce (43). 
Nevertheless, several hospital based studies (44 – 60) 
highlighted the contribution of hypertension to mor-
bidity and mortality among black African patients. 
Hypertension-related complications were responsible 
for around 20% of all adult medical admissions in 
two reports from Nigeria (44,45) and one from South 
Africa (46). In recently published series (47 – 50,59), 
the prevalence of hypertension among patients with 
heart failure ranged from 33.3% (49) to 69.6% (60). 
It was 77.8% (50) and 51.0% (51) among stroke 
patients below age 45 years and in the general popu-
lation, respectively, and 49.0% and 45.6% among 
Ghanaian (54) and South African (55) patients with 
end-stage renal disease. Hypertension was a comorbid-
ity in 51.9% patients with aortic aneurysm admitted 
to a tertiary referral hospital in Kenya (61). We recently 
assessed the frequency and determinants of in-hospital 
mortality among patients admitted for hypertension to 
two city hospitals in Mbuji Mayi, Congo (58). Among 
401 consecutive patients (mean age 54.3 years; 129 
women), 89 (22.2%) died over a median follow-up of 
15 days. The multivariable-adjusted probability of 
death increased with systolic pressure ( p   0.0013) 
on admission (58). In a Nigerian teaching hospital in 
Enugu, the case-fatality rate among patients admitted 
because of hypertension was 42.9% (56). 
 Figure 2. Number of patients screened, enrolled and randomized 
on December 1, 2010. The dotted line indicates the number of 
patients to be randomized. 
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262  A. N. Odili et al. 
 By design, the NOAAH trial closely follows the 
ESC/ESH (9) and several African (15 – 17) guide-
lines. First, NOAAH patients have uncomplicated 
grade-1 or grade-2 hypertension with no more than 
two additional risk factors. Diabetes, renal dysfunc-
tion and previous cardiovascular disease are exclu-
sion criteria. Thus, NOAAH patients have a low to 
moderate increased risk above the average. For such 
patients, the guidelines (9,15 – 17) propose that life-
style changes should fi rst be recommended and rein-
forced for several weeks (grade 2) or even months 
(grade 1) before antihypertensive drug treatment is 
initiated. These recommendations (9,15 – 17) explain 
why having a 4-week run-in period without blood 
pressure lowering treatment should not raise ethical 
concerns. The run-in period allows us to ascertain 
the diagnosis of hypertension with greater certainty. 
Second, as recommended by most current guidelines 
(8 – 10, 14 – 18), combination therapy is used to initiate 
antihypertensive treatment in NOAAH patients. The 
advantages of combination therapy are: tighter and 
earlier blood pressure control than monotherapy or 
sequential combination therapy, respectively; simpli-
fi cation of the therapeutic regimen and therefore better 
adherence; avoidance of dose-dependent adverse 
effects experienced with higher doses of single agents; 
and attenuation of the adverse effects of some agents 
when used alone. Third, Blacks have a higher sensi-
tivity to salt intake and an impaired ability to excrete 
ingested salt. This leads to an overall expansion 
of intravascular volume. According to the ABCD 
algorithm (62,63), both treatment arms of NOAAH 
include a drug class that addresses the low-renin vol-
ume component of hypertension (hydrochlorothiaz-
ide and amlodipine) as well as agents (bisoprolol and 
valsartan) interfering with the high-renin vasocon-
strictor component (63). Diuretics and calcium-
channel blockers potentiate the effi cacy of renin 
system inhibitors in Black low-renin patients (64). 
 The lower-dose reference medication in NOAAH 
is the combination of bisoprolol 5 mg plus 6.25 mg 
hydrochlorothiazide. Given once daily, this combina-
tion lowers blood pressure throughout 24 h (65,66) 
and signifi cantly more than bisoprolol 5 mg/day or 
hydrochlorothiazide 25 mg/day given as single com-
ponents (66). A double-blind parallel group dose-
escalation trial involved 539 patients with uncomplicated 
mild-to-moderate hypertension, who were random-
ized to the combination of bisoprolol plus hydrochlo-
rothiazide (2.5/6.25, 5/6.25 and 10/6.25 mg/day, 
enalapril (5, 10, 20 mg/day) or amlodipine (2.5, 5, 
10 mg/day) for a period of 12 weeks. The combina-
tion was at least as effective as amlodipine and more 
effective than enalapril in both women and men (67). 
Findings were similar in a combined analysis (68) of 
two studies (69,70), in which, after stratifi cation for 
ethnicity, 114 Blacks and 427 non-Blacks were ran-
domized and followed up for 12 weeks. In Blacks, the 
combination of bisoprolol plus hydrochlorothiazide 
resulted in signifi cantly greater reductions of systolic 
and diastolic blood pressure than enalapril or pla-
cebo, but was not signifi cantly different from amlo-
dipine (68). In non-Blacks, the combination produced 
greater reductions in diastolic blood pressure than 
amlodipine or enalapril (68). The placebo-corrected 
decreases in blood pressure and the control rates 
were similar in Blacks and non-Blacks. In both eth-
nicities, the discontinuation rate related to uncon-
trolled blood pressure or adverse events was lowest 
on the combination (68). 
 Experimental treatment in NOAAH consists of 
the combination of amlodipine plus valsartan. One 
report based on two randomized, double-blind, pla-
cebo-controlled, trials addressed the blood pressure 
lowering effi cacy of several combinations of these 
components (71). Both studies consisted of a 2-week 
washout period, which was followed by a single-
blind, placebo run-in period of 2 – 4 weeks, and there-
after by an 8-week, double-blind, active-treatment 
period. In the fi rst study, the daily doses were 2.5 to 
5 mg for amlodipine and 40, 80, 160 or 320 mg for 
valsartan; in the second study, they were 10 mg for 
amlodipine and 160 or 320 mg for valsartan. In 2478 
patients, the blood pressure reductions were larger 
with the combinations than with the corresponding 
monotherapy components with a positive dose-
response for all combinations (Table II) (71). In 
3155 patients analyzed for safety, the overall rate of 
adverse effects on combination therapy (44.5%) was 
similar on amlodipine (45.7%), but larger than on 
valsartan monotherapy (39.8%). Peripheral edema 
occurred less on the combination (5.4%) than on 
amlodipine given alone (8.7%), but more frequently 
than on valsartan monotherapy (2.1%) or placebo 
(3.0%). The corresponding rates of headache were 
4.3%, 7.6%, 4.8% and 5.9%, respectively (71). The 
rate of adverse events leading to discontinuation 
of the treatment was low on combination therapy 
(1.8%) and comparable with that on placebo (2.1%). 
Angiotensin II receptor blockers dilate postcapillary 
vessels and therefore reduce the transmural pressure 
in the capillary bed, which is increased on mono-
therapy by dihydropyridines by precapillary vasodi-
latation. This explains the reduction of ankle edema 
on combination therapy (72,73). Other trials com-
paring the combination of amlodipine plus valsartan 
in Black (74) or predominantly White (75,76) patients 
were confi rmatory. 
 Clinical research in developing countries differs 
in several ways from that in developed countries, 
partly because of the cultural differences, relatively 
poor health care and research infrastructure, wide 
socioeconomic divide within the society, illiteracy of 
patients, and lack of suffi cient numbers of trained 
investigators and support personnel in these coun-
tries (77). For these reasons, we did not implement 
self-measurement of blood pressure at home. We also 
organized three investigators ’ meetings to overcome 
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these diffi culties and to familiarize the clinical 
researchers with all aspects of the trial. By design, 
NOAAH is a simple trial, in which intentionally the 
number of biochemical measurements is limited to 
those required to assess safety. All data traffi c between 
the clinical sites and SCC is organized as email 
attachment. This setup does not require constant 
Internet access and allows immediate quality control 
and feedback on receipt of data. ECGs are recorded 
using a paperless device not requiring consumables 
and software that allows analysis of heart rate vari-
ability in the frequency domain (78). Four centers 
participate in pulse wave analysis and measurement 
of pulse wave velocity. In this ancillary study, we will 
assess the infl uence of older versus newer drugs on 
the central blood pressure and arterial stiffness and 
investigate whether we can reproduce fi ndings in 
White hypertensive patients (79). Thus, although 
simple in design, NOAAH is poised to move knowl-
edge forward. The trial is only running in countries, 
in which the randomized medications are marketed 
and available to patients after they left the trial. 
 In conclusion, current guidelines strongly sup-
port the use of combination therapy as fi rst-line 
treatment in hypertensive patients. However, to our 
knowledge, there is presently little information on 
blood pressure lowering effi cacy and rate of adverse 
events on fi xed combinations consisting of older ver-
sus newer drugs in Black hypertensive patients born 
and living in sub-Saharan Africa. NOAAH will gen-
erate this information by the end of 2011. On March 1, 
2011, 237 patients had been enrolled in the run-in 
period and over 136 had been randomized. 
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